ArriVent BioPharma (AVBP) Net Income (2023 - 2026)
ArriVent BioPharma (AVBP) posted Net Income of -$83.4 million for Q1 2026, down 133.45% sequentially from -$35.7 million in Q4 2025, and up 11.22% YoY from -$75.0 million in Q1 2025.
ArriVent BioPharma (AVBP) Net Income (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Net Income for 4 years, with the latest figure at -$83.4 million in Q1 2026.
- Quarterly Net Income rose 11.22% year-over-year to -$83.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$251.0 million (down 7.46% YoY) and the FY2025 annual result came in at -$198.0 million, down 51.32% from the prior year.
- Net Income slipped to -$83.4 million in Q1 2026 per AVBP's latest filing, from -$35.7 million in the prior quarter.
- Over five years, Net Income peaked at -$12.2 million in Q1 2023 and troughed at -$93.9 million in Q1 2025.
- A 4-year average of -$49.9 million and a median of -$55.0 million in 2024 frame the typical range for Net Income.
- The widest YoY moves for Net Income: up 67.55% in 2024, down 340.46% in 2024.
- Over 4 years, Net Income stood at -$65.3 million in 2023, then jumped by 67.55% to -$21.2 million in 2024, then plunged by 68.5% to -$35.7 million in 2025, then slumped by 133.45% to -$83.4 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$83.4 million, -$35.7 million, and -$63.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | -164.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -164.99 Mn |
| Mar 31, 2026 | -83.37 Mn |
| Dec 31, 2025 | -35.71 Mn |
| Sep 30, 2025 | -63.45 Mn |
| Jun 30, 2025 | -68.42 Mn |
| Mar 31, 2025 | -93.91 Mn |
| Dec 31, 2024 | -21.19 Mn |
| Sep 30, 2024 | -63.43 Mn |
| Jun 30, 2024 | -55.00 Mn |
| Mar 31, 2024 | -50.38 Mn |
| Dec 31, 2023 | -65.32 Mn |
| Sep 30, 2023 | -14.40 Mn |
| Jun 30, 2023 | -21.57 Mn |
| Mar 31, 2023 | -12.17 Mn |